NZ741483A - Antibody and protein formulations - Google Patents
Antibody and protein formulationsInfo
- Publication number
- NZ741483A NZ741483A NZ741483A NZ74148313A NZ741483A NZ 741483 A NZ741483 A NZ 741483A NZ 741483 A NZ741483 A NZ 741483A NZ 74148313 A NZ74148313 A NZ 74148313A NZ 741483 A NZ741483 A NZ 741483A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- tfpi
- salt
- antibody formulation
- seq
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Provided are salt-free antibody and other protein formulations that are substantially isosmotic and of low viscosity. In particular, provided is: A salt-free anti-TFPI antibody formulation, comprising: 10 mM to 30 mM histidine; 50 ppm to 200 ppm of a non-ionic surfactant; 88 mM to 292 mM of sucrose; 10 mM to 50 mM arginine; 0 mM to 50 mM lysine; 0 mM to 133 mM glycine or alanine; 0 mM to 10 mM methionine; and 1 mg/ml to 150 mg/ml of anti-TFPI human IgG2 antibody having a light chain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 2, wherein said anti-TFPI antibody formulation has a pH of pH 4.0 to pH 6.0, and wherein said anti-TFPI antibody formulation contains substantially no inorganic salt. Also provided is the use of these formulations in the manufacture of medicaments for the treatment of disorders in patients.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/601,598 US8613919B1 (en) | 2012-08-31 | 2012-08-31 | High concentration antibody and protein formulations |
| US13/843,780 US9592297B2 (en) | 2012-08-31 | 2013-03-15 | Antibody and protein formulations |
| NZ70486613 | 2013-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ741483A true NZ741483A (en) | 2020-07-31 |
Family
ID=72265387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ741483A NZ741483A (en) | 2012-08-31 | 2013-08-28 | Antibody and protein formulations |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ741483A (en) |
-
2013
- 2013-08-28 NZ NZ741483A patent/NZ741483A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ705178A (en) | Anti-prolactin receptor antibody formulations | |
| HRP20191299T1 (en) | Antibody formulations | |
| NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| BR112012019098A2 (en) | Medical treatment and/or a medicine constituent for prevention of cancer | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| FI3310809T3 (en) | ANTI-CGRP ANTIBODY FORMULATION | |
| IN2014KN01714A (en) | ||
| TN2012000478A1 (en) | Long - acting formulations of insulins | |
| MX360211B (en) | Pharmaceutical composition for treatment and/or prevention of cancer. | |
| ES2531083T3 (en) | Stable polypeptide formulations and uses thereof | |
| PE20141151A1 (en) | CD27L ANTIGEN BINDING PROTEINS | |
| EA201492021A1 (en) | ANTI-COMPOSITION | |
| ECSP088962A (en) | NEW HERBICIDES | |
| NZ601114A (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies | |
| NZ630885A (en) | Antibody formulation | |
| IN2014KN01715A (en) | ||
| BR112015014760A2 (en) | zinc-amino acid complex with cysteine | |
| BR112013019513A2 (en) | Methods for treating diabetic foot ulcers | |
| PH12016502430B1 (en) | Method for decreasing immunogenicity of protein and peptide | |
| PH12015502063A1 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
| UA117480C2 (en) | Treatment of diabetes mellitus by long–acting formulations of insulins | |
| EA201491513A1 (en) | RECOMBINANT STRAINS ESCHERICHIA COLI | |
| AR128395A2 (en) | NOVEL PEPTIDES ABLE TO INDUCE THE FORMATION OF ANTIBODIES AGAINST PCSK9 |